Standards of care for treatment of recurrent glioblastoma - are we there yet?

Newly diagnosed glioblastoma is now commonly treated with surgery, if feasible, or biopsy, followed by radiation plus concomitant and adjuvant temozolomide. The treatment of recurrent glioblastoma continues to be a moving target as new therapeutic principles enrich the standards of care for newly di...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Weller, Michael (VerfasserIn) , Cloughesy, Timothy (VerfasserIn) , Perry, James R. (VerfasserIn) , Wick, Wolfgang (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2013
In: Neuro-Oncology
Year: 2013, Jahrgang: 15, Heft: 1, Pages: 4-27
ISSN:1523-5866
DOI:10.1093/neuonc/nos273
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/neuonc/nos273
Volltext
Verfasserangaben:Michael Weller, Timothy Cloughesy, James R. Perry, and Wolfgang Wick

MARC

LEADER 00000caa a2200000 c 4500
001 1775900959
003 DE-627
005 20230426125444.0
007 cr uuu---uuuuu
008 211102s2013 xx |||||o 00| ||eng c
024 7 |a 10.1093/neuonc/nos273  |2 doi 
035 |a (DE-627)1775900959 
035 |a (DE-599)KXP1775900959 
035 |a (OCoLC)1341422374 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Weller, Michael  |d 1962-  |e VerfasserIn  |0 (DE-588)130838039  |0 (DE-627)506356701  |0 (DE-576)29836834X  |4 aut 
245 1 0 |a Standards of care for treatment of recurrent glioblastoma - are we there yet?  |c Michael Weller, Timothy Cloughesy, James R. Perry, and Wolfgang Wick 
264 1 |c 2013 
300 |a 24 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Advance Access publication November 7, 2012 
500 |a Gesehen am 02.11.2021 
520 |a Newly diagnosed glioblastoma is now commonly treated with surgery, if feasible, or biopsy, followed by radiation plus concomitant and adjuvant temozolomide. The treatment of recurrent glioblastoma continues to be a moving target as new therapeutic principles enrich the standards of care for newly diagnosed disease. We reviewed PubMed and American Society of Clinical Oncology abstracts from January 2006 to January 2012 to identify clinical trials investigating the treatment of recurrent or progressive glioblastoma with nitrosoureas, temozolomide, bevacizumab, and/or combinations of these agents. At recurrence, a minority of patients are eligible for second surgery or reirradiation, based on appropriate patient selection. In temozolomide-pretreated patients, progression-free survival rates at 6 months of 20%-30% may be achieved either with nitrosoureas, temozolomide in various dosing regimens, or bevacizumab. Combination regimens among these agents or with other drugs have not produced evidence for superior activity but commonly produce more toxicity. More research is needed to better define patient profiles that predict benefit from the limited therapeutic options available after the current standard of care has failed. 
700 1 |a Cloughesy, Timothy  |e VerfasserIn  |4 aut 
700 1 |a Perry, James R.  |e VerfasserIn  |4 aut 
700 1 |a Wick, Wolfgang  |d 1970-  |e VerfasserIn  |0 (DE-588)120297736  |0 (DE-627)080586929  |0 (DE-576)186221320  |4 aut 
773 0 8 |i Enthalten in  |t Neuro-Oncology  |d Oxford : Oxford Univ. Press, 1999  |g 15(2013), 1, Seite 4-27  |h Online-Ressource  |w (DE-627)357167341  |w (DE-600)2094060-9  |w (DE-576)318041839  |x 1523-5866  |7 nnas  |a Standards of care for treatment of recurrent glioblastoma - are we there yet? 
773 1 8 |g volume:15  |g year:2013  |g number:1  |g pages:4-27  |g extent:24  |a Standards of care for treatment of recurrent glioblastoma - are we there yet? 
856 4 0 |u https://doi.org/10.1093/neuonc/nos273  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20211102 
993 |a Article 
994 |a 2013 
998 |g 120297736  |a Wick, Wolfgang  |m 120297736:Wick, Wolfgang  |d 910000  |d 911100  |e 910000PW120297736  |e 911100PW120297736  |k 0/910000/  |k 1/910000/911100/  |p 4  |y j 
999 |a KXP-PPN1775900959  |e 3998504249 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Michael Weller, Timothy Cloughesy, James R. Perry, and Wolfgang Wick"]},"id":{"doi":["10.1093/neuonc/nos273"],"eki":["1775900959"]},"relHost":[{"origin":[{"publisher":"Oxford Univ. Press ; Duke University Medical Center","dateIssuedDisp":"1999-","dateIssuedKey":"1999","publisherPlace":"Oxford ; Durham, NC"}],"pubHistory":["1.1999 -"],"id":{"zdb":["2094060-9"],"eki":["357167341"],"issn":["1523-5866"]},"part":{"volume":"15","year":"2013","text":"15(2013), 1, Seite 4-27","extent":"24","issue":"1","pages":"4-27"},"title":[{"title_sort":"Neuro-Oncology","title":"Neuro-Oncology","subtitle":"official journal of the World Federation of Neuro-Oncology"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 21.07.23"],"recId":"357167341","physDesc":[{"extent":"Online-Ressource"}],"disp":"Standards of care for treatment of recurrent glioblastoma - are we there yet?Neuro-Oncology"}],"person":[{"display":"Weller, Michael","family":"Weller","role":"aut","given":"Michael"},{"display":"Cloughesy, Timothy","family":"Cloughesy","given":"Timothy","role":"aut"},{"family":"Perry","role":"aut","given":"James R.","display":"Perry, James R."},{"given":"Wolfgang","role":"aut","family":"Wick","display":"Wick, Wolfgang"}],"origin":[{"dateIssuedKey":"2013","dateIssuedDisp":"2013"}],"title":[{"title_sort":"Standards of care for treatment of recurrent glioblastoma - are we there yet?","title":"Standards of care for treatment of recurrent glioblastoma - are we there yet?"}],"note":["Advance Access publication November 7, 2012","Gesehen am 02.11.2021"],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1775900959","physDesc":[{"extent":"24 S."}]} 
SRT |a WELLERMICHSTANDARDSO2013